Insulet (PODD) Misses Q2 EPS by 14c, Sales Beat

Insulet (NASDAQ: PODD) reported Q2 EPS of ($0.27), $0.14 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $75.6 million versus the consensus estimate of $70.75 million.

Insulet sees FY2015 revenue of $300-320 million, versus the consensus of $304.4 million.

"We are very pleased with our second quarter performance, which was better than expected," said Patrick Sullivan, President and Chief Executive Officer. "Successful execution of our key initiatives and our new leadership team's increased focus, sense of urgency and accountability are beginning to generate results. We are energized by the progress we are making and are excited about our future opportunities as we further increase adoption of OmniPod in the U.S. and international markets. Looking ahead, we believe we are well-positioned to continue our momentum and drive stronger top-line growth in the second half of the year."

For earnings history and earnings-related data on Insulet (PODD) click here.

You May Also Be Interested In

• Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Offic
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c